TipRanks
Advertisement
Advertisement

CLYM Stock Latest News

Climb Bio added to ‘Analysts Current Favorites’ at Raymond James
The FlyClimb Bio added to ‘Analysts Current Favorites’ at Raymond James
17d ago
CLYM
TYRA
Climb Bio price target raised to $25 from $18 at Oppenheimer
PremiumThe Fly
Climb Bio price target raised to $25 from $18 at Oppenheimer
1M ago
CLYM
JBIO
Climb Bio price target raised to $30 from $24 at H.C. Wainwright
PremiumThe Fly
Climb Bio price target raised to $30 from $24 at H.C. Wainwright
1M ago
CLYM
Climb Bio management to meet with Piper Sandler
PremiumThe Fly
Climb Bio management to meet with Piper Sandler
1M ago
CLYM
Climb Bio price target raised to $30 from $26 at B. Riley
PremiumThe Fly
Climb Bio price target raised to $30 from $26 at B. Riley
1M ago
CLYM
Jade Biosciences price target raised to $48 from $25 at Clear Street
PremiumThe FlyJade Biosciences price target raised to $48 from $25 at Clear Street
1M ago
CLYM
JBIO
Climb Bio price target raised to $32 from $20 at BTIG
Premium
The Fly
Climb Bio price target raised to $32 from $20 at BTIG
1M ago
CLYM
Climb Bio price target raised to $25 from $21 at Baird
Premium
The Fly
Climb Bio price target raised to $25 from $21 at Baird
1M ago
CLYM
Climb Bio price target raised to $40 from $23 at Piper Sandler
PremiumThe Fly
Climb Bio price target raised to $40 from $23 at Piper Sandler
1M ago
CLYM
Matt Phipps Initiates Buy on Climb Bio, Citing Strong Early CLYM116 Data and Support for Once‑Every‑12‑Weeks Dosing Strategy
PremiumRatings
Matt Phipps Initiates Buy on Climb Bio, Citing Strong Early CLYM116 Data and Support for Once‑Every‑12‑Weeks Dosing Strategy
1M ago
CLYM
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data
PremiumCompany Announcements
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data
1M ago
8K
CLYM
Climb Bio announces initial data from CLYM116 trial
PremiumThe Fly
Climb Bio announces initial data from CLYM116 trial
1M ago
CLYM
Climb Bio price target raised to $24 from $20 at H.C. Wainwright
PremiumThe FlyClimb Bio price target raised to $24 from $20 at H.C. Wainwright
2M ago
CLYM
CLYM116’s Differentiated APRIL ‘Sweeper’ Design Sets Up Phase I Data as Key Catalyst for IgA Nephropathy Outlook
Premium
Ratings
CLYM116’s Differentiated APRIL ‘Sweeper’ Design Sets Up Phase I Data as Key Catalyst for IgA Nephropathy Outlook
2M ago
CLYM
Climb Bio Advances Phase 2 Renal Disease Trial
Premium
Company Announcements
Climb Bio Advances Phase 2 Renal Disease Trial
2M ago
8K
CLYM
Climb Bio price target raised to $25 from $17 at Truist
PremiumThe Fly
Climb Bio price target raised to $25 from $17 at Truist
2M ago
CLYM
Climb Bio Advances Budoprutug Lupus Trial, Keeping Investors Tuned to Early-Stage Data
PremiumCompany Announcements
Climb Bio Advances Budoprutug Lupus Trial, Keeping Investors Tuned to Early-Stage Data
2M ago
CLYM
Climb Bio reports Q2 EPS (18c), consensus (21c)
PremiumThe Fly
Climb Bio reports Q2 EPS (18c), consensus (21c)
2M ago
CLYM
Climb Bio initiated with an Outperform at RBC Capital
PremiumThe Fly
Climb Bio initiated with an Outperform at RBC Capital
2M ago
CLYM
Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst
PremiumCompany AnnouncementsClimb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst
2M ago
CLYM
Climb Bio: Unique APRIL Inhibitor Profile Supports Buy Rating and Unchanged $20 Price Target
Premium
Ratings
Climb Bio: Unique APRIL Inhibitor Profile Supports Buy Rating and Unchanged $20 Price Target
3M ago
CLYM
Climb Bio Appoints Breanna O’Reilly to Board
Premium
Company Announcements
Climb Bio Appoints Breanna O’Reilly to Board
3M ago
8K
CLYM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >